Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1990 May;34(5):792-5.
doi: 10.1128/AAC.34.5.792.

Vancomycin pharmacokinetics in burn patients and intravenous drug abusers

Affiliations

Vancomycin pharmacokinetics in burn patients and intravenous drug abusers

M J Rybak et al. Antimicrob Agents Chemother. 1990 May.

Abstract

The pharmacokinetics of vancomycin were evaluated in 34 patients (10 burn patients, 14 intravenous drug abusers [IVDA], and 10 controls). Multiple serum samples were drawn following a 1-h vancomycin infusion at steady state over an 8- to 12-h dosing interval. Pharmacokinetic parameters were derived by noncompartmental analysis. There were no significant differences among the groups with respect to age, weight, serum creatinine, volume of distribution, or protein binding. Burn patients had a significantly higher creatinine clearance than did IVDA or controls. Vancomycin clearances averaged 142.8, 98.0, and 67.7 ml/min in burn patients, IVDA, and controls, respectively. The renal clearance of vancomycin was also higher in burn patients than in the other groups. IVDA tended to have a higher vancomycin clearance (31% higher) than did controls, but the difference was not statistically significant. Vancomycin clearance was much higher in burn patients requiring dosage individualization and close monitoring. A considerable amount of vancomycin was eliminated through renal tubular secretion, making dosage predictions based on creatinine clearance more difficult. Further work with IVDA will be needed to determine if they represent a group requiring aggressive vancomycin dosages.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Pharmacol Exp Ther. 1982 Jul;222(1):237-40 - PubMed
    1. Clin Pharmacokinet. 1980 Nov-Dec;5(6):548-56 - PubMed
    1. Comput Programs Biomed. 1983 Jun;16(3):203-16 - PubMed
    1. J Pharm Sci. 1984 Feb;73(2):281-2 - PubMed
    1. J Antimicrob Chemother. 1984 Dec;14 Suppl D:53-7 - PubMed